Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone
about
Pharmacogenetics of antipsychotic adverse effects: Case studies and a literature review for cliniciansMolecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugsMaribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adultsCytochrome P450 polymorphisms and response to antipsychotic therapy.The significance of QT interval in drug development.The effect of risperidone on D-amino acid oxidase activity as a hypothesis for a novel mechanism of action in the treatment of schizophrenia.Interactions between the cytochrome P450 system and the second-generation antipsychotics.Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10/*10Metabolic drug interactions with new psychotropic agents.Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers.Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypesRole of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents.Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study.The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia.Paliperidone-ER: first atypical antipsychotic with oral extended release formulation.Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release.Pharmacogenomic Study Reveals New Variants of Drug Metabolizing Enzyme and Transporter Genes Associated with Steady-State Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Thai Autism Spectrum Disorder Patients.Atypical antipsychotics: trends in analysis and sample preparation of various biological samples.The pharmacology and formulation of paliperidone extended release.Pharmacogenetics of clinical response to risperidone.Pharmacogenomics can improve antipsychotic treatment in schizophrenia.Clinical applications of CYP genotyping in psychiatry.Switching atypical antipsychotics: a review.Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients.Quantitative prediction of cytochrome P450 (CYP) 2D6-mediated drug interactions.Impact of Ageing on Serum Concentrations of Risperidone and Its Active Metabolite in Patients with Known CYP2D6 Genotype.Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort.Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety.Urinary retention caused after fluoxetine-risperidone combination.Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies.Correlation between scores on Continuous Performance Test and plasma concentration for schizophrenic patients on risperidone.QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations.Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients.Interpreting serum risperidone concentrations.CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: implications for clinical practice and genetic testing.Evaluation of the clinical efficacy of risperidone for untreated and treated cases of schizophrenia from various aspects.Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone.Development and Validation of Liquid Chromatography/Tandem Mass Spectrometry Analysis for Therapeutic Drug Monitoring of Risperidone and 9-Hydroxyrisperidone in Pediatric Patients with Autism Spectrum Disorders.The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions.
P2860
Q24657338-E5C73386-9046-4852-A7A9-F174F6C5AB62Q24683013-B1142E87-C209-4DFD-B610-FB20D864E2F7Q34510611-E750CFBA-9661-45C4-8256-186C58DB63C7Q34612118-D953AD64-B864-4B1B-B53C-0FFAE25F67EBQ34808276-182B6FC0-A680-4B4A-BA2D-46E3204C4C95Q34970798-D38A0B42-D0D2-479C-B36B-B56C4BA6D63BQ35096587-C2EB2658-AEF9-4BA0-9B27-BFA0084037FBQ35287206-1E597EAF-6F7C-4EE3-999E-A1C68E3AB7DDQ35619640-2C3DF516-E208-408E-9390-62289F47F8A8Q35753607-BBAF7702-3B8D-4A90-9D9F-4824B1CD2767Q35826139-70B03FB5-7233-470D-8DD4-24F3C64B1DFCQ36522045-87CCDC23-A32D-4808-B203-3DD680E88DEBQ36969067-0C14C198-E795-451C-AA1E-D516CFA5D19EQ36984231-6A1C45D7-AC6F-42FF-A691-C6380AB681AAQ37083634-94B45B1E-E4F8-4A50-B27E-74471263A81DQ37422493-D767FE66-805F-425E-88F4-8AB77899C036Q37488898-73419D1C-59B3-4A4D-ADDD-09487A527F81Q38005440-8C395805-26F6-48C2-984C-675019F34672Q38067139-3C4BB544-4E9F-4EB2-A280-614815A32C6FQ38074712-EC6B0C8E-3018-4FE5-867C-14F627A5AC7DQ38100731-5B74C2DD-92B0-4981-B918-E532D4BDBB6BQ38247063-BD7558F6-BFC6-4D43-8DD6-22824417AACEQ38777655-3E38F637-E6C7-4C0D-8F91-946399A94817Q39228215-AA9B53A2-00A6-470A-A6A4-6A6C769CEC90Q39730908-67F8C7F7-5C92-4041-BBBD-18F4AD2B7E00Q39795136-884A2A72-B5BD-49D7-8BC6-C7B4634AF64CQ40780592-5B3D3878-786E-4C29-B2DD-7A5A64E27A1DQ43120631-7FBC59C1-A1DF-4D21-A14D-FC3478E992AFQ43670032-844529D4-B56D-416E-9C51-E5AA7F53C48DQ44343565-4648EC30-8132-4AF1-A5BF-FBEEDCDDAE72Q44624989-B78DD599-0785-4D43-B035-FE732E561D8CQ44792438-C2F9C01B-16FF-4167-BBCE-C05E99711F3EQ44983984-8428D527-6032-46DD-8B48-CCBC45B12A9DQ45991893-565F00FF-2864-4F8B-8FBB-82A1055EE050Q46083513-78AC0815-492C-4006-B999-2358ADB2558FQ46564749-173E1FFF-6F98-4285-A282-B919758105C2Q46728122-3FCECD7C-E789-4DB3-80CB-2A26E976259FQ46840675-F201CD9D-707F-4404-95B5-E9E9EA29973AQ47898060-9F8569B0-B1EF-42BC-B9D8-CADCBBECF2B3Q48107672-C0C45EE6-AA61-4BC9-9028-9C644FF70A37
P2860
Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Cytochrome P450 2D6 genotype a ...... idone and 9-hydroxyrisperidone
@ast
Cytochrome P450 2D6 genotype a ...... idone and 9-hydroxyrisperidone
@en
Cytochrome P450 2D6 genotype a ...... idone and 9-hydroxyrisperidone
@nl
type
label
Cytochrome P450 2D6 genotype a ...... idone and 9-hydroxyrisperidone
@ast
Cytochrome P450 2D6 genotype a ...... idone and 9-hydroxyrisperidone
@en
Cytochrome P450 2D6 genotype a ...... idone and 9-hydroxyrisperidone
@nl
prefLabel
Cytochrome P450 2D6 genotype a ...... idone and 9-hydroxyrisperidone
@ast
Cytochrome P450 2D6 genotype a ...... idone and 9-hydroxyrisperidone
@en
Cytochrome P450 2D6 genotype a ...... idone and 9-hydroxyrisperidone
@nl
P2093
P356
P1433
P1476
Cytochrome P450 2D6 genotype a ...... idone and 9-hydroxyrisperidone
@en
P2093
P2888
P304
P356
10.1007/S002130051171
P407
P577
1999-12-01T00:00:00Z
P6179
1053447250